Skip to content

HKPD

Cellyan Biotechnology Ltd.

NASDAQ · Healthcare · Medical - Pharmaceuticals · HK

$0.13
−8.86%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+2.3%
EBITDA
EBIT
Net income
EPS
Free cash flow

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026